The Asia Pacific Plasma Fractionation Market was valued at $5822.6 Million in 2026 and projected to reach to $8714.7 Million by 2031, representing a compound annual growth rate of 8.4%. The Asia Pacific plasma fractionation market is positioned for sustained growth through 2031, driven by demographic shifts, rising disease prevalence, and expanding healthcare access across the region.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific plasma fractionation market is projected to grow from USD 5,822.6 million in 2026 to USD 8,714.7 million by 2031, representing a robust 8.4% CAGR, outpacing the global average of 7.6%.
Increasing prevalence of immunodeficiency disorders and autoimmune diseases across Asia Pacific is driving significant demand for immunoglobulin therapies, a key plasma fractionation product segment.
Growing incidence of hemophilia, von Willebrand disease, and other bleeding disorders in Asia Pacific populations is fueling demand for clotting factor concentrates and related plasma-derived therapeutics.
Substantial government and private sector investments in healthcare infrastructure, diagnostic capabilities, and biopharmaceutical manufacturing across Asia Pacific are creating favorable conditions for market growth.
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
|
|
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma | Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity |
|
|
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release | Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | SCIG (Type) |
| Forecast Period | 2026-2030 |
| Growth Rate | CAGR of 7.6% from 2026 to 2030 |
| Largest Segment | THERAPEUTICS (Application) |
| Market Size Base Year (Billions) | ~USD 36.46 (2026) |
| Revenue Forecast (Billions) | ~USD 48.87 (2030) |
| Segments Covered | Product, Type, Application, Therapeutic Area, End User |
5 segment dimensions are covered across the global market.
| Country | 2025 size (native) |
|---|---|
| China | USD 5216.6 Million |
| Japan | USD 1328.1 Million |
| India | USD 432.2 Million |
| South Korea | USD 310.2 Million |
| Australia | USD 1055.5 Million |
| Vietnam | USD 49.5 Million |
| Malaysia | USD 61.7 Million |
| Indonesia | USD 99.3 Million |
Asia Pacific's plasma fractionation market is projected to reach USD 8,714.7 million by 2031, growing from USD 5,822.6 million in 2026.
Asia Pacific's plasma fractionation market is expected to grow at a compound annual growth rate of 8.4% between 2026 and 2031.
Asia Pacific growth is driven by increasing prevalence of bleeding disorders, rising demand for immunoglobulin therapies, expanding healthcare infrastructure, and improving patient access to plasma-derived treatments.
Asia Pacific's 8.4% CAGR outpaces the global market CAGR of 7.6%, positioning the region as a high-growth segment within the global plasma fractionation industry.
Emerging economies including India, Southeast Asian nations, and China are primary growth drivers in Asia Pacific, supported by rising healthcare spending and improving regulatory frameworks.
This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..
The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.
Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.
With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report